Azilsartan medoxomil for the treatment of hypertension

Drugs of Today

Volumn 47, Issue 9, 2011, Pages 647-651

  Vasiliou, S ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AZILSARTAN MEDOXOMIL; CANDESARTAN HEXETIL; CHLORTALIDONE; OLMESARTAN; PIOGLITAZONE; PLACEBO; RAMIPRIL; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ATTENUATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERINSULINEMIA; HYPERPHAGIA; HYPOKALEMIA; LOADING DRUG DOSE; NONHUMAN; NONSENSE MUTATION; PERIPHERAL EDEMA; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; OXADIAZOLES; PRODRUGS; TREATMENT OUTCOME;

EID: 80053967631     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.9.1688573     Document Type: Review

References (26)

1. Epstein, B.J. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manage 2010, 6(1): 711-22.
2. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 2001, 103(6): 904-12. (Pubitemid 32163892)
3. Bakris, G.L., Sica, D., Weber, M. et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertension 2011, 13(2): 81-8.
4. White, W.B., Weber, M.A., Sica, D., Bakris, G.L., Perez, A., Cao, C., Kupfer, S. Effects of the angiotensin receptor blockerazilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011, 57(3): 413-20.
5. Zhao, M., Li, Y., Wang, J. et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011, Epub ahead of print.
6. Ye, Y., Keyes, K.T., Zhang, C.F., Perez-Polo, J.R., Lin, Y., Birnbaum, Y. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther 2010, 24(2): 107-20.
7. Efficacy and safety of azilsartan in subjects with essential hypertension (NCT00759551). ClinicalTrials.gov Web site, July 5, 2011.
8. Safety and efficacy of azilsartan medoxomil in participants with mild to moderate hypertension (NCT00362115). ClinicalTrials.gov Web site, July 5, 2011.
9. Efficacy and safety of azilsartan in participants with mild to moderate uncomplicated essential hypertension (NCT01289132). ClinicalTrials.gov Web site, July 5, 2011.
10. Efficacy and safety of azilsartan medoxomil in African-American participants with essential hypertension (NCT00591253). ClinicalTrials.gov Web site, July 5, 2011.
11. Johnson, W., White, W.B., Sica, D. et al. Efficacy and safety of azilsartan medoxomil, a novel angiotensin II receptor blocker, in African-Americans with hypertension. J Clin Hypertension [25th Annu Sci Meet Am Soc Hypertens (ASH) (May 1-4, New York) 2010] 2010, 12(1, Suppl.): Abst PO-232.
12. Efficacy and safety of azilsartan medoxomil in participants with essential hypertension (NCT00696241). ClinicalTrials.gov Web site, July 5, 2011.
13. Bakris, G., Sica, D., Weber, M., White, W.B., Perez, A., Cao, C., Kupfer, S. Results of a novel angiotensin receptor blocker, azilsartan medoxomil, in patients with primary hypertension. J Hypertension [20th Eur Meet Hypertens (June 18-21, Oslo) 2010] 2010, 28(Suppl.): Abst 9A.01.
14. Bakris, G., Sica, D., Weber, M., White, W.B., Perez, A., Cao, C., Kupfer, S. Effects of the novel angiotensin receptor blocker azilsartan medoxomil in patients with primary hypertension. J Clin Hypertension [25th Annu Sci Meet Am Soc Hypertens (ASH) (May 1-4, New York) 2010] 2010, 12(1, Suppl.): Abst PO-221.
15. Efficacy and safety comparison of azilsartan medoxomil to valsartan in participants with essential hypertension (NCT00591578). ClinicalTrials.gov Web site, July 5, 2011.
16. Sica, D., White, W.B., Weber, M.A., Bakris, G. L., Perez, A., Cao, C., Kupfer, S. New angiotensin II receptor blocker azilsartan medoxomil: comparison to valsartan. J Hypertension [20th Eur Meet Hypertens (June 18-21, Oslo) 2010] 2010, 28(Suppl.): Abst PP.16.86.
17. An efficacy and safety study of azilsartan medoxomil compared to valsartan and olmesartan in participants with essential hypertension (NCT00696436). ClinicalTrials.gov Web site, July 5, 2011.
18. White, W., Weber, M., Sica, D., Bakris, G., Perez, A., Cao, C., Kupfer, S. The new angiotensin receptor blocker azilsartan medoxomil has significantly greater 24-hour blood pressure lowering efficacy to both olmesartan and valsartan. J Hypertension [20th Eur Meet Hypertens (June 18-21, Oslo) 2010] 2010, 28(Suppl.): Abst 9D.05.
19. White, W.B., Weber, M.A., Sica, D., Bakris, G. L., Perez, A., Cao, C., Kupfer, S. The new angiotensin receptor blocker azilsartan medoxomil has superior 24-hour blood pressure lowering efficacy to both olmesartan and valsartan. J Clin Hypertension [25th Annu Sci Meet Am Soc Hypertens (ASH) (May 1-4, New York) 2010] 2010, 12(1, Suppl.): Abst PO-242.
20. Efficacy and safety study of azilsartan medoxomil compared to ramipril for treating essential hypertension (NCT00760214). ClinicalTrials.gov Web site, July 5, 2011.
21. Bönner, G., Bakris, G. L., Sica, D. et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertension [20th Eur Meet Hypertens (June 18-21, Oslo) 2010] 2010, 28(Suppl.): Abst PP.16.112.
22. Efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in participants with essential hypertension (NCT00591266). ClinicalTrials.gov Web site, July 5, 2011.
23. Weber, M.A., White, W.B., Sica, D., Bakris, G. L., Perez, A., Cao, C., Kupfer, S. Antihypertensive efficacy of the novel angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. J Hypertension [20th Eur Meet Hypertens (June 18-21, Oslo) 2010] 2010, 28(Suppl.): Abst PP.16.99.
24. Weber, M.A., White, W.B., Sica, D., Bakris, G. L., Perez, A., Cao, C., Kupfer, S. Antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. J Clin Hypertension [25th Annu Sci Meet Am Soc Hypertens (ASH) (May 1-4, New York) 2010] 2010, 12(1, Suppl.): Abst PO-241.
25. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension (NCT00591773). ClinicalTrials.gov Web site, July 5, 2011.
26. Sica, D., Bakris, G.L., White, W.B., Weber, M.A., Perez, A., Cao, C., Kupfer, S. New angiotensin II receptor blocker azilsartan medoxomil coadministered with chlorthalidone provides potent blood pressure reduction in stage 2 hypertension. J Clin Hypertension [25th Annu Sci Meet Am Soc Hypertens (ASH) (May 1-4, New York) 2010] 2010, 12(1, Suppl.): Abst PO-238.